In this activity, Dr. Alison Moskowitz explains the importance of determining prognostic risk when treating patients who are newly diagnosed with Hodgkin lymphoma and what tools clinicians should use.
Dr. Anas Younes discusses the immune-related toxicities clinicans should be mindful of when prescribing a new checkpoint inhibitor and what you can do to help treat these side effects.
Join Dr. Matasar as he discusses how to decide if a newly diagnosed Hodgkin lymphoma patient needs to have a bone marrow biopsy as part of their initial workup.
Join Dr. Ansell as he will discuss the two main issues in today's management of front-line classical Hodgkin lymphoma, including bleomycin and radiation therapy.
Join Dr. John Sweetenham as he discusses the role of brentuximab vedotin as first-line salvage therapy prior to ASCT and ongoing studies using BV in combination with other conventional regimens.
Dr. Ansell discusses what future changes may lie ahead beyond current treatment options in frontline therapy, focusing on new clinical trial results with brentuximab vedotin.